Background: Eczema is a common chronic inflammatory disease of the skin. Studies suggest differences in disease prevalence and severity by race/ethnicity. Our knowledge of health care utilization for eczema among different racial/ethnic groups remains limited.
Eczema is a common chronic inflammatory disease of the skin that is associated with significant negative physical and psychosocial effects. [1] [2] [3] [4] [5] The prevalence of childhood eczema in the United States is estimated at 10% or more 6, 7 and differs by race and ethnicity, with the disease being more common among non-Hispanic black children (17.1% prevalence) than among nonHispanic whites (11.2%) and Hispanic whites (13.7%). 7, 8 Eczema might also be more severe among racial/ethnic minority children, though the exact nature of this relationship remains unclear. 6 Although data suggest that at least the physical burden of eczema might be greater among racial/ethnic minority children, it remains unclear if health care utilization for childhood eczema reflects this greater burden.
Previous studies have found lower health care utilization among racial/ ethnic minorities across multiple medical conditions including an aggregate of dermatologic diseases. [9] [10] [11] [12] Racial/ethnic minority children also have poorer access to medical care including primary care. 13, 14 Few studies have specifically examined health care utilization for eczema by race/ethnicity. Two studies using data from the National Ambulatory Medical Care Survey or the National Hospital Ambulatory Medical Care Survey found minority race/ethnicity to be associated with increased health care utilization as measured by ambulatory visits for eczema. 15, 16 However, these studies were limited by their inclusion of only those individuals with eczema who were accessing medical care. Thus, the purpose of our study was to evaluate health care utilization among all children with eczema by race/ethnicity at a population level and with individual-level granularity using data from the Medical Expenditure Panel Surveys.
METHODS

Study design and data source
We conducted a cohort study using data from the Medical Expenditure Panel Survey (MEPS), which generates estimates that are nationally representative of the US civilian noninstitutionalized population and is the most complete source of data on health care utilization, cost, and health insurance coverage in the United States. 17 The 18 The study was granted exempt status by the University of Pennsylvania Institutional Review Board.
Study population
Our study population was limited to survey respondents reporting atopic dermatitis or eczema (ICD-9 codes 691 or 692). Both ICD-9 codes were included because of low prevalence and probable underutilization of the more specific ICD-9 691 code. Analyses were further limited to respondents aged 0-17 years, a pediatric population that is more likely to have true atopic dermatitis. Respondents from years 2001-2013, years in which there were consistent reporting options for race/ethnicity, were pooled for analyses. Lastly, only those individuals who self-identified as non-Hispanic white, non-Hispanic black, and Hispanic white were included as the sample sizes of other races were too small to generate stable estimates.
Definitions of exposure and covariates
The Longitudinal Files provided information on race/ethnicity (the primary explanatory variable or exposure) categorized as non-Hispanic white (reference), non-Hispanic black, and Hispanic white, age, sex, census region, health insurance type, household income level, and survey years. Information on age and census region was collected at the time of interview for each of the 5 survey rounds; health insurance type and household
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income level was collected for each of the 2 years of follow-up. Age and census region from the interview round during which eczema was first reported was used. Health insurance type and household income level from the first year of study follow-up was used if eczema was first reported in interview rounds 1-3. Health insurance type and household income level from the second year was used if eczema was first reported in rounds 4 or 5. If information could not be ascertained using the delineated algorithm, then data from the closest available time point was used. Comorbid asthma (ICD-9 code 493) or allergies (ICD-9 code 477) were identified from the Medical Conditions Files. Duration of eczema follow-up in terms of number of interview rounds was determined from the round in which eczema was first reported until the end of an individual's or survey follow-up.
Definitions of outcome measures
Health care utilization outcomes were separately evaluated for 2 cohorts: (1) all individuals with caregiver-reported eczema, and (2) those individuals with eczema who had accessed medical care (ie, reported $1 ambulatory visit) for eczema. Among the entire cohort, the outcome of interest was any ambulatory visit for eczema (dichotomized as $1 versus no visits). Among those who accessed medical care, the outcomes of interest were number of ambulatory visits, number of prescriptions obtained, and any dermatology ambulatory visit for eczema. The number of office-based medical provider visits, outpatient department visits, and prescribed medicines obtained for eczema were obtained from the Medical Conditions Files. The total number of ambulatory visits for eczema was derived from the sum of office-based medical provider visits and outpatient department visits for eczema and did not include emergency visits. The number of health care utilization events (ie, ambulatory visits and prescriptions obtained for eczema) per year was calculated by dividing the number of health care utilization events over the 2-year follow-up period by the number of rounds of eczema follow-up and multiplying by the expected 2.5 rounds of follow-up per year (based on 5 interview rounds over the 2-year follow-up period). Ambulatory dermatology visits for eczema were determined by linking records corresponding to eczema from the Medical Conditions Files to Office-Based Provider Visit Files and Outpatient Department Visit Files containing information on provider specialty. Provider specialty was only fully available for years 2002-2013, thus analyses examining associations with ambulatory dermatology visits were limited to these years.
Statistical analyses
Each survey panel served as a 2-year cohort, and panels were pooled across the years. One individual (0.05% [unweighted]) had incomplete covariate information and was excluded from all analyses. Bivariate analyses between race/ethnicity and other population characteristics were examined using the Rao-Scott design-based x 2 test for categorical variables and the global F-test from linear regression analysis for continuous variables. Odds ratios (ORs) for the association between dichotomous health care utilization outcomes (ie, any ambulatory visit for eczema among the full cohort and any ambulatory dermatology visit for eczema among those who accessed medical care for eczema) and race/ ethnicity were calculated using logistic regression. Incidence rate ratios (IRRs) for the association between number of ambulatory visits for eczema and race/ethnicity among individuals who accessed medical care for eczema were calculated using zerotruncated negative binomial regression, accounting for duration of eczema follow-up. IRRs for the association between number of prescriptions obtained for eczema and race/ethnicity among individuals who accessed medical care for eczema were calculated by using negative binomial regression, accounting for duration of eczema follow-up. In all analyses, multivariable regression was used to adjust for age, sex, variables that were identified a priori as conceptually important to the questions of interest, and variables that were significantly associated with race/ethnicity (P \ .05) in bivariate analyses. We also tested for hypothesized interactions between race/ethnicity and the following: a) health insurance status, b) household income, and c) comorbid asthma in select analyses. All analyses accounted for the complex survey design and population-based weights using Stata 14.0 (StataCorp, College Station, TX) SVY commands and the appropriate variables for strata, primary sampling units, and longitudinal weights as specified in the Pooled Linkage Variance Estimation File. 
RESULTS
A total of 2043 surveyed individuals were aged 0-17 years and reported having eczema. This sample is representative of [2.9 million children with eczema in the United States with a racial/ethnic composition of 65.8% non-Hispanic white, 18.3% non-Hispanic black, and 15.9% Hispanic white. In bivariate analyses (Table I) , minority children (non-Hispanic blacks and Hispanic whites) were significantly younger, less likely to have any private insurance, more likely to fall into the low-income category, and more likely to have asthma relative to non-Hispanic white children. Additional differences in census region of residence, duration of eczema follow-up, and survey panel number were observed by race/ethnicity.
Overall, 59.6% of children with eczema had an ambulatory visit for their disease over the 2-year follow-up period (Table II; 62.1% non-Hispanic white, 51.9% non-Hispanic black, and 58.1% Hispanic white). In adjusted analyses accounting for age, sex, census region, insurance status, household income, comorbid asthma, duration of eczema follow-up, and survey year, non-Hispanic blacks had a 30% lower odds of having an ambulatory visit for eczema during the 2-year follow-up period than non-Hispanic whites (adjusted OR [OR adj ] 0.69; 95% confidence interval [CI] 0.51-0.92). Interactions between race/ethnicity and both insurance status and household income were evaluated and were not found to be statistically significant; the ORs for an ambulatory visit for eczema were not significantly affected by insurance status or household income across racial/ethnic groups (data not shown).
In contrast, among individuals who accessed medical care for eczema, non-Hispanic blacks had significantly more ambulatory visits (adjusted IRR 
DISCUSSION
In our study of a nationally representative sample of children with caregiver-reported eczema, we found that non-Hispanic blacks were less likely to report an ambulatory visit for eczema than non-Hispanic whites. However, among those who had accessed medical care (ie, had $1 ambulatory visit for eczema), non-Hispanic blacks reported more visits and prescriptions obtained for eczema and were more likely to report a dermatology visit for eczema than non-Hispanic whites. Importantly, our findings were independent of baseline sociodemographic factors, health insurance status, and presence of atopic comorbidities, all of which might have affected access to health care, 13, 19 suggesting that race alone predicts whether or not a child sees a medical provider for eczema in the ambulatory setting.
Our population-based study adds to the limited existing literature on health care utilization for eczema in children 5, 15, 16 by examining racial/ethnic differences in multiple health care utilization outcomes with granularity at the individual level. Unlike prior studies using the National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey data samples of all US office-based and hospital outpatient and emergency department visits, 15, 16 respectively, use of MEPS data allowed us to evaluate health care utilization among all individuals with eczema regardless of whether or not they were accessing medical care for their skin disease. Our analyses were also performed only among individuals with reported eczema, thus, minimizing confounding by racial/ethnic differences in eczema prevalence. Furthermore, our multivariable analyses adjusted for baseline differences in sociodemographic factors, health insurance status, and atopic comorbidities, allowing us to assess the independent association between race/ethnicity and health care utilization for eczema. Collectively, our findings suggest a newly identified disparity in Unweighted total N = 1207; weighted total N = 1,737,369. All analyses accounted for the complex survey design and population-based weights. CI, Confidence interval; IRR adj , adjusted incidence rate ratios; IRR unadj , unadjusted incidence rate ratios; ref, referent. *The mean estimated number of prescriptions obtained for eczema per year was calculated by dividing the number of prescriptions obtained for eczema over the 2-year follow-up period by the number of rounds of eczema follow-up and multiplying by the expected 2.5 rounds of follow-up per year. y IRR unadj and 95% CI accounted for the duration of eczema follow-up using the exposure parameter specification. z IRR adj and 95% CI were adjusted for age (continuous), sex, region, health insurance, household income, comorbid asthma, and panel number, accounting for the duration of eczema follow-up using the exposure parameter specification. Unweighted total N = 1207; weighted total N = 1,737,369. All analyses accounted for the complex survey design and population-based weights. CI, Confidence interval; IRR adj , adjusted incidence rate ratio; IRR unadj , unadjusted incidence rate ratio; ref, referent. *The mean estimated number of ambulatory visits per year was calculated by dividing the number of ambulatory visits for eczema over the 2-year follow-up period by the number of rounds of eczema follow-up and multiplying by the expected 2.5 rounds of follow-up per year. y IRR unadj and 95% CI accounted for duration of eczema follow-up using the exposure parameter specification. z IRR adj were adjusted for age (continuous), sex, census region, health insurance, household income, comorbid asthma, and panel number, accounting for duration of eczema follow-up using the exposure parameter specification.
ambulatory care for non-Hispanic black children with eczema compared with non-Hispanic whites.
In line with a previous study that found more severe childhood eczema to be associated with increased health care utilization, 5 our observation of greater health care utilization for eczema among non-Hispanic black compared with white children who had accessed medical care suggests more severe skin disease among the minority group. If, in fact, this is the case, the disparity in ambulatory visits among all non-Hispanic black versus white children with eczema could indicate an even greater gap in care. Notably, this gap in eczema care is not entirely explained by financial or insurance barriers to medical care, per our analyses, and might be reflective of differences in other factors, such as social environment or stressors, recognition or understanding of eczema, trust in the medical system, access to high-quality care, among others, that need to be identified.
Beyond race/ethnicity, we identified additional characteristics to be associated with health care utilization for eczema. Among children who had accessed medical care for eczema, comorbid asthma was also associated with a greater number of total ambulatory visits and prescriptions obtained for eczema but was not associated with having seen a dermatologist. Nonspecialty health care utilization might be partially driven by asthma-related health care in conjunction with eczema care provided by nondermatologists in the pediatric population. 20 The documented association between eczema severity and asthma might also be a contributing factor. 5 For dermatology visits, higher household income was associated with greater likelihood of having seen a dermatologist for eczema. Considering prior studies suggesting greater eczema prevalence 21 and severity 6 among those of lower income, our observation might be driven by greater access to specialty care among those with higher income rather than disease severity.
Limitations of our study include the following: (1) information on health conditions and health care utilization were based on caregiver report and might be subject to recall bias and underreporting of eczema as suggested by the lower than expected number of children with reported eczema; (2) heterogeneous definition of eczema due to use of collapsed 3-digit ICD-9-CM codes and general underutilization of the more specific atopic dermatitis code (691); (3) small sample sizes of other racial/ethnic minority groups that prevented analysis; (4) potential for unmeasured confounders such as geographic proximity to health care providers; and (5) lack of direct measures of eczema severity.
Nevertheless, our findings shed important light on the status of ambulatory care for childhood eczema in the United States. Identifying the non-Hispanic black race to be independently associated with lower ambulatory health care utilization for childhood eczema suggests the presence of barriers to health care for eczema among this minority group irrespective of income and insurance status, despite likely having more severe skin disease. Further research is necessary to understand what these additional barriers are and why they exist. Ultimately, increasing the awareness and understanding of these disparities in health care utilization is essential to providing equitable care and improving outcomes for all individuals with eczema.
